JS Genetics
Develops and markets proprietary, low cost, high value DNA diagnostic testsfor underserved medical conditions in newborns, children, and adolescents. This focus grew out of the recognition that most genetic tests require blood samples, have longer turn-around times, and are expensive. The Company's principle strategy is to internally develop tests using cheek swabs for sample collection and a PCR based testing platform to bring to market accurate, convenient and cost effective DNA screening tests for adolescents focused in three key areas of developmental disorders:
Physical Development:
Turner Syndrome
Klinefelter Syndrome
Down's Syndrome
Cognitive Development:
Dyslexia
Behavioral Development:
Fragile X
X Chromosome Abnormality Test (XCAT)
PCR and quantitative pyrosequencing based technology uses a simple cheek swab to accurately determine chromosomal abnormalities.
XCAT-TS: Is a novel molecular genetic test for detection of Classic and Mosaic Turner Syndrome. This test is now available - to order kits click here.
Read more...
XCAT-KS: Is a genetic test for Klinefelter Syndrome, one of the most common genetic abnormalities in males. This test is currently in clinical validation trials and is scheduled to be commercially available in the fourth quarter of 2011. Read more...
XCAT-FX: Is a test for Fragile X Syndrome, the most common hereditary cause of mental impairment in men and a major cause of infertility among women. The commercial availability of this product is planned for 1H 2012. Read more...
XCAT-DS: Is a test for Down’s Syndrome/Trisomy 18. Early stage development work is underway for this product. Read more...
All of the analytical work is performed in our lab is CLIA certified and CAP Accredited laboratory
CLIA ID# 07D1091103 CAP accredited CAP# 721-5351
News
JS Genetics Chooses XIFIN for Revenue Cycle Management and Commercialization Strategies.More...
JS Genetics receives CAP accreditation from College of American Pathology. More...
JS Genetics presents to Yale & CURE BioHaven Entrepreneurship Series. More...
NICHD approves JS Genetics funding for a NIH Phase 2 Development of Novel Diagnostic More...
Results of XCAT-TS validation Study are published in the Journal of Clinical Endocrinology & Metabolism…More
JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome More...